Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors

Table 5 Multivariate survival analysis - categorical methylation data

Covariate	Baseline	Coefficient(b_i)	HR(exp(b_i)	p-value	95,0%CI for Exp(B)
TP53	TP53 wild type	−2.332	0.097	6.6e-5	(0.030-0.305)
ER	ER positive	1.481	4.401	0.008	(1.460-13.269)
Stage II	Stage I	2.260	9.584	0.013	(1.593-57.667)
Stage III	Stage I	−0.011	0.988	0.992	(0.088-11.019)
N1	N0	−6.362	0.529	0.338	(0.143-1.947)
N2	N0	1.673	5.332	0.047	(1.019-27.885)
IGF2	Normal like IGF2	1.597	4.940	0.009	(1.472-16.581)
GSTP1	Normal like GSTP1	−1.621	0.197	0.014	(0.053-0.729)
PPP2R2B	Normal like PPP2R2B	−0.972	0.378	0.085	(0.125-1.143)
CDKN2A	Normal like CDKN2A	−0.839	0.432	0.133	(0.144-1.294)

The variables that the minimum AIC selected. ( p-values: 3.4e-7 for likelihood ratio test, 3.4e-4 for Wald test, 3.2e-6 for log-rank test).
Positive hazard ratios indicate an increased risk of dying from breast cancer and are calculated for the different covariates.

ISSN: 1471-2407